Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-depressant drug and its oral particulate agent and pharmacy purpose thereof

An anti-depressant and granule technology, applied in the field of medicine, can solve problems such as prolonging the time of taking medicine and increasing the dose

Active Publication Date: 2018-11-06
程世宏
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, increasing the dose and prolonging the time of taking the drug will cause withdrawal symptoms such as anxiety and sleep disturbance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-depressant drug and its oral particulate agent and pharmacy purpose thereof
  • Anti-depressant drug and its oral particulate agent and pharmacy purpose thereof
  • Anti-depressant drug and its oral particulate agent and pharmacy purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Oral granules for the treatment of depression

[0036] Prescription of raw and auxiliary materials: mirtazapine 12g, compound (VIIIA) 2g, mannitol 247.2g, hydroxypropyl methylcellulose 96g, aspartame 2.4g and an appropriate amount of purified water.

[0037] Preparation:

[0038] The prescription amount of mirtazapine and compound (VIIIA) were pulverized through 80 mesh sieve to obtain main drug powder; the prescription amount of mannitol, hydroxypropyl methylcellulose and aspartame were respectively pulverized through 60 mesh sieve to obtain excipient powder ; Mix the main ingredient powder and auxiliary material powder evenly, add purified water to prepare soft material, pass through a 30-mesh sieve to granulate, dry in vacuum at 30°C for 60 minutes, granulate with a 24-mesh sieve, and pack separately.

Embodiment 2

[0039] Example 2 Oral granules for the treatment of depression

[0040] Prescription of raw and auxiliary materials: 10 g of mirtazapine, 2 g of compound (VIIIA), 206 g of mannitol, 80 g of hydroxypropyl methylcellulose, 2 g of aspartame and an appropriate amount of purified water.

[0041] Preparation:

[0042] The prescription amount of mirtazapine and compound (VIIIA) were pulverized through 80 mesh sieve to obtain main drug powder; the prescription amount of mannitol, hydroxypropyl methylcellulose and aspartame were respectively pulverized through 60 mesh sieve to obtain excipient powder ; Mix the main ingredient powder and auxiliary material powder evenly, add purified water to prepare soft material, pass through a 30-mesh sieve to granulate, dry in vacuum at 30°C for 60 minutes, granulate with a 24-mesh sieve, and pack separately.

Embodiment 3

[0043] Embodiment 3 oral granules for treating depression

[0044] Prescription of raw and auxiliary materials: 10 g of mirtazapine, 2 g of compound (VIIIB), 206 g of mannitol, 80 g of hydroxypropyl methylcellulose, 2 g of aspartame and an appropriate amount of purified water.

[0045] Preparation method: take the prescribed amount of mirtazapine and compound (VIIIB) and pulverize them through a 80-mesh sieve to obtain the main drug powder; take the prescribed amount of mannitol, hydroxypropyl methylcellulose and aspartame and pulverize them through a 60-mesh sieve respectively, Obtain auxiliary material powder; mix the main drug powder and auxiliary material powder evenly, add purified water to prepare a soft material, granulate through a 30-mesh sieve, vacuum-dry at 30°C for 60 minutes, granulate with a 24-mesh sieve, and pack separately.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine, and especially relates to an anti-depressant drug and its oral particulate agent and a pharmacy purpose thereof. The anti-depressant drug is prepared bya pharmaceutical adjuvant, mirtazapine and an isoquinoline compound. The pharmaceutical adjuvant of the oral particulate agent comprises mannitol, hydroxypropyl methyl cellulose, citric acid and aspartame. With low dosage usage of mirtazapine, the anti-depressant drug can perform obvious anti-depression effect and has good safety.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an antidepressant medicine, oral granules and pharmaceutical application thereof. Background technique [0002] Depression is a common mood disorder syndrome characterized by low mood, reduced social willingness, and suicidal tendencies. The disease is a mental disease that seriously endangers the physical and mental health of human beings. With the acceleration of the pace of life and the increase of social pressure, the incidence of the disease shows a clear upward trend and a younger trend. According to the World Health Organization, there are currently 340 million depression patients in the world, and the number of depression patients in China has exceeded 26 million. 28.5-63.7% of depressed patients have suicidal behavior, and about 15% eventually commit suicide. [0003] The exact pathogenesis of depression is still unclear. There are currently many hypotheses on the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/55A61K31/4741A61K9/16A61P25/24
CPCA61K9/1623A61K9/1652A61K31/4741A61K31/55A61P25/24A61K2300/00
Inventor 程世宏汪婧王倩燕徐虹
Owner 程世宏
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com